Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Titan Pharmaceuticals

Titan Pharmaceuticals

Titan Pharmaceuticals is a small Molecules founded in 1992.

All edits

Edits on 19 Sep, 2022
Katrina-Kay Pettitt"prospector:1906:1375905"
Katrina-Kay Pettitt edited on 19 Sep, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Edits on 22 Jul, 2022
Golden AI"clean up phone number value"
Golden AI edited on 22 Jul, 2022
Edits made to:
Infobox (+1/-1 properties)
Infobox
Phone number
650-244-4990
Phone number
+16502444990
Edits on 15 Jul, 2022
Patrick Pum
Patrick Pum edited on 15 Jul, 2022
Edits made to:
Infobox (+7 properties)
Infobox
DUNS Number
807182720
Board of Directors
CAGE code
47F74
CIK number
IRS number
943,171,940
Place of incorporation
SIC code
2,836
Edits on 30 Jun, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 30 Jun, 2022
Infobox
Wikidata ID
Edits on 19 Jun, 2022
Golden AI"Infobox creation from: Wikidata data enrichment"
Golden AI approved a suggestion from Golden's AI on 19 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Location
Duzenko Andrey
Duzenko Andrey edited on 19 Jun, 2022
Edits made to:
Infobox (+2/-4 properties)
Infobox
Exchange
Stock symbol
TTNP
Wikidata ID
Full address
400 OYSTER POINT BLVD STE 505 SOUTH SAN FRANCISCO, CA 94080 UNITED STATES
Headquarters
Location
Headquarters
Edits on 10 Jun, 2022
Golden AI"Entity importer update"
Golden AI edited on 10 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 6 Jun, 2022
N Ni
N Ni edited on 6 Jun, 2022
Edits made to:
Infobox (+6 properties)
Infobox
Legal name
Titan Pharmaceuticals Inc.
Exchange
Fax number
650-244-4956
Full address
400 Oyster Point Boulevard, Suite 505 South San Francisco, CA, 94080-1958
Number of Employees (ranges)
10 – 19
Phone number
650-244-4990
Ticker symbol
TTNP
Edits on 21 May, 2022
Ирина Носкова"Edit from table cell"
Ирина Носкова edited on 21 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Company Operating Status
Active
Edits on 3 May, 2022
Alexey Polysaev"Edit from table cell"
Alexey Polysaev edited on 3 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Alexey Polysaev"Edit from table cell"
Alexey Polysaev edited on 3 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
1992
Alexey Polysaev"Edit from table cell"
Alexey Polysaev edited on 3 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 8 Apr, 2022
Golden AI"Patent autocalculation"
Golden AI edited on 8 Apr, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Patents assigned (count)
5
Edits on 12 Feb, 2022
N Ni
N Ni edited on 12 Feb, 2022
Edits made to:
Article (+1748 characters)
Article

Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases.

Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

ProNeura consists of a small, semi-rigid, flexible implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is placed subcutaneously, normally in the inner part of the upper arm, in a simple office procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.

...

Titan’s first product based on its ProNeura technology was Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, Titan announced its decision to discontinue selling its Probuphine implant in the U.S. and wind down its commercialization activities, and to pursue a plan that will enable it to focus on its ProNeura-based product development programs. For additional information regarding Probuphine, click here.

Edits on 14 Dec, 2021
Golden AI"Remove inverse infobox"
Golden AI edited on 14 Dec, 2021
Edits on 4 Dec, 2021
Golden AI
Golden AI edited on 4 Dec, 2021
Edits on 1 Nov, 2021
Golden AI"Inferring industry - ai.social_media_extractor.01"
Golden AI edited on 1 Nov, 2021
Edits made to:
Infobox (+1/-1 properties)
Infobox
Edits on 9 Oct, 2021
Henry Ogolla"Approved suggestion from source: https://twitter.com/titanpharma"
Henry Ogolla approved a suggestion from Golden's AI on 9 Oct, 2021
Edits made to:
Topic thumbnail

Titan Pharmaceuticals

Small Molecules

Edits on 7 Oct, 2021
Keeri Tramm"prospector:635:227583"
Keeri Tramm edited on 7 Oct, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Edits on 28 Jun, 2021
Erin Scherfner"prospector:338:165756"
Erin Scherfner edited on 28 Jun, 2021
Edits made to:
Infobox (+1 properties)
Description (+15 characters)
Topic thumbnail

Titan Pharmaceuticals

Small Molecules

Infobox
Golden logo
By using this site, you agree to our Terms & Conditions.